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Author’s declarative title: Alpha2 agonist dexmedetomidine may reduce duration of delirium in 
critically ill adults. 
 
 
 
Commentary on: Burry L, et al. Pharmacological interventions for the treatment of delirium in 
critically ill adults. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD011749. 
DOI: 10.1002/14651858.CD011749.pub2. 
 
 
Commentary  
Implications for practice and research  
 
• Alpha2 agonist dexmedetomidine may reduce duration of delirium. 
• Cholinesterase inhibitor rivastigmine may prolong the duration of delirium and length of 
intensive care. 
• Future research should ensure that important clinical outcomes are reported such as 
symptom management. 
 
Context 
 
Delirium is a multifaceted neurocognitive indication of an underlying medical condition (1).  
It frequently occurs in critically ill patients and can have substantial negative consequences with 
increased mortality and intensive care unit (ICU) length of stay (2). Uncertainty remains around 
the effectiveness of pharmacological interventions for the treatment of delirium within ICU (3). 
This Cochrane systematic review aims to examine the effectiveness of pharmacological 
interventions for treating delirium in critically ill adults with a confirmed or documented high risk 
of delirium (3).  
 
 
Methods 
 
A comprehensive peer-reviewed search of nine electronic databases was carried out from date of 
inception to 21 March 2019, supplemented by searches of systematic reviews and grey literature. 
Only Randomized Controlled Trials (RCTs) or quasi RCTs which compared the effectiveness of any 
pharmacological intervention to another pharmacological/nonpharmacological intervention or 
placebo in critically ill adults were included. A robust screening, data extraction and quality 
assessment (Cochrane risk of bias criteria and overall summary quality using GRADE) was 
undertaken by two independent reviewers with arbitration by a third reviewer. Evidence 
synthesis was undertaken using a Pairwise random effects meta-analysis and a network meta-
analysis. 
 
Findings 
 
Fourteen trials with 1,844 participants examining six different drug classes (antipsychotics, alpha2 
agonists, statins, opioids, serotonin antagonists and cholinesterase inhibitors) for treating 
delirium in critically ill adults were included in the review.  Of the 14 trials, nine were judged to 
be of low risk of bias with the overall quality of the included studies ranging from low to high. 
 
Only two studies showed any statistically significant effect from the active treatment compared 
to placebo in pairwise comparisons. Although one study (71 participants, moderate quality 
evidence) found a reduction in delirium duration from dexmedetomidine (alpha2 antagonist), 
another study (114 participants, moderate quality evidence) reported an increase in duration of 
delirium and length of intensive care stay following treatment with cholinesterase inhibitors. 
None of the other drugs showed a statistically significant change in delirium duration, delirium-
free and coma-free days, days with coma, and length of stay. Limited evidence prevented NMAs 
of long-term cognitive outcomes or mortality.  
 
The limited benefit of the six drug classes compared to placebo were emphasised through a 
network meta-analysis (NMA). Despite alpha2 antagonists being ranked in the NMA as the best 
in in reducing the duration of mechanical ventilation and length of stay the reduction was not 
statistically significant. 
 
 
Commentary  
 
Looking at the quality of the review using the Amstar2 tool, this review is of high quality and 
provides an accurate and comprehensive summary of the results of the available studies that 
address the question of interest.  
 
Despite the common use of pharmacological interventions in managing delirium (4) only the 
alpha2 agonist dexmedetomidine was found to have a small statistically significant effect in 
duration of delirium compared to placebo. Furthermore, no other pharmacological intervention 
had any effect on delirium duration, or any other secondary outcomes reported in this review. 
Concerningly cholinesterase inhibitor was associated with harms and as such, guidelines suggest 
against its use for treatment of ICU delirium (3). Although, reported adverse events in the included 
studies were similar between the pharmacological intervention and placebo it is important to 
note that these two findings of alpha2 agonist dexmedetomidine and cholinesterase inhibitor 
were from only one relatively small study each and these findings may change with additional 
new evidence. There is a growing interest in this area, currently 10 studies which are ongoing and 
six which are awaiting classification have been identified to have large sample sizes, which may 
change the estimations of effect identified within this review. 
 
As well as these ongoing trials, further research should ensure that important clinical outcomes 
are reported such as symptom management, for example stopping treatment interferences and 
treating agitation. Wherever possible core outcome sets should be used.  It is also important 
that future research ensures reporting possibly confounding variables such as early mobilization 
and physical restraints. 
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